Identification of Topoisomerase I Mutations Affecting Both DNA Cleavage and Interaction with Camptothecin a

[1]  D. Hall,et al.  Detailed analysis of the basic domain of the E2F1 transcription factor indicates that it is unique among bHLH proteins. , 1994, Oncogene.

[2]  D. Kufe,et al.  Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. , 1994, The Journal of biological chemistry.

[3]  O. Westergaard,et al.  Characterization of intra- and intermolecular DNA ligation mediated by eukaryotic topoisomerase I. Role of bipartite DNA interaction in the ligation process. , 1994, The Journal of biological chemistry.

[4]  S. Shuman,et al.  Requirements for noncovalent binding of vaccinia topoisomerase I to duplex DNA. , 1994, Nucleic acids research.

[5]  Y. Pommier,et al.  Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. , 1993, The Journal of biological chemistry.

[6]  J. Wang,et al.  Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. , 1993, Cancer research.

[7]  B. Gatto,et al.  DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Traktman,et al.  Biochemical analysis of mutant alleles of the vaccinia virus topoisomerase I carrying targeted substitutions in a highly conserved domain. , 1993, The Journal of biological chemistry.

[9]  A. Andersen,et al.  Eukaryotic topoisomerase I-mediated cleavage requires bipartite DNA interaction. Cleavage of DNA substrates containing strand interruptions implicates a role for topoisomerase I in illegitimate recombination. , 1993, The Journal of biological chemistry.

[10]  A. Bodley,et al.  A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. , 1993, Cancer research.

[11]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[12]  J. Alsner,et al.  Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. , 1993, Nucleic acids research.

[13]  J. Alsner,et al.  Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. , 1992, Journal of molecular biology.

[14]  N. Saijo,et al.  Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. , 1992, Biochemical and biophysical research communications.

[15]  S. Shuman,et al.  Covalent and noncovalent DNA binding by mutants of vaccinia DNA topoisomerase I. , 1992, The Journal of biological chemistry.

[16]  Peggy J. Farnham,et al.  Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties , 1992, Cell.

[17]  J. Svejstrup,et al.  New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site. , 1991, Journal of molecular biology.

[18]  S. Shuman.  Site-specific interaction of vaccinia virus topoisomerase I with duplex DNA. Minimal DNA substrate for strand cleavage in vitro. , 1991, The Journal of biological chemistry.

[19]  J. Wang,et al.  DNA topoisomerases: why so many? , 1991, The Journal of biological chemistry.

[20]  N. Osheroff,et al.  Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers. , 1990, The EMBO journal.

[21]  R. Hertzberg,et al.  Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site. , 1990, The Journal of biological chemistry.

[22]  M. Nissen,et al.  The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. , 1990, The Journal of biological chemistry.

[23]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[24]  R. Sternglanz,et al.  Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I. , 1989, The Journal of biological chemistry.

[25]  M. McHugh,et al.  Effect of minor groove binding drugs on mammalian topoisomerase I activity. , 1989, Biochemical pharmacology.

[26]  R. Hertzberg,et al.  On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. , 1989, Biochemistry.

[27]  E. Di Mauro,et al.  Regulation of the function of eukaryotic DNA topoisomerase I: topological conditions for inactivity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Kohn,et al.  Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin. , 1988, Nucleic acids research.

[29]  L. Bolund,et al.  Sequence-dependent effect of camptothecin on human topoisomerase I DNA cleavage. , 1988, Journal of molecular biology.

[30]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[31]  Y. Suzuki,et al.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Burgess,et al.  Nucleotide sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV40 DNA. , 1984, Nucleic acids research.

[33]  L. Liu,et al.  Recognition sites of eukaryotic DNA topoisomerase I: DNA nucleotide sequencing analysis of topo I cleavage sites on SV40 DNA. , 1982, Nucleic acids research.

[34]  J. Champoux,et al.  The effect of salt on the binding of the eucaryotic DNA nicking-closing enzyme to DNA and chromatin. , 1981, Biochimica et biophysica acta.